Equities

Neurosense Therapeutics Ltd

NRSN:NAQ

Neurosense Therapeutics Ltd

Actions
  • Price (USD)0.92
  • Today's Change-0.070 / -7.08%
  • Shares traded143.52k
  • 1 Year change+76.99%
  • Beta--
Data delayed at least 15 minutes, as of Nov 21 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments2.647.0911
Total Receivables, Net0.240.130.18
Total Inventory------
Prepaid expenses--0.120.13
Other current assets, total0.040.040.04
Total current assets2.927.3811
Property, plant & equipment, net0.250.310.02
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets3.197.7111
LIABILITIES
Accounts payable1.460.500.04
Accrued expenses--1.160.56
Notes payable/short-term debt000
Current portion long-term debt/capital leases--0.06--
Other current liabilities, total2.00----
Total current liabilities3.461.730.60
Total long term debt0.070.150
Total debt0.070.210
Deferred income tax------
Minority interest------
Other liabilities, total1.410.221.83
Total liabilities4.942.092.43
SHAREHOLDERS EQUITY
Common stock00--
Additional paid-in capital242617
Retained earnings (accumulated deficit)(26)(21)(8.45)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity(1.76)5.629.01
Total liabilities & shareholders' equity3.197.7111
Total common shares outstanding151211
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.